Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences reported Q1 2026 net revenues of $1.98 million, an 18% decline year-over-year driven by a 33% drop in U.S. sales due to generic L-Glutamine competition. The company posted a net loss of $3.3 million ($0.05 per share), widening from $2.3 million in the prior year, primarily due to higher other expenses including interest and derivative fair value changes.
Key figures
- Revenue
- 1982000
- Revenue Yoy
- -18%
- Gross profit
- 1814000
- Weighted avg shares
- 70188263
- Cash and equivalents
- 1072000
- Total current liabilities
- 70581000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.